# OnCo record nct06956170 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06956170/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06956170", "NCT06956170" ;
  schema:name "All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo"@en ;
  schema:description "A phase 3 trial of Belantamab mafodotin, Pomalidomide, Dexamethasone in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06956170/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06956170> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-02-10" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/antiemetic-therapy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/protac-degrader/> ;
  onco:drugs <https://onco.cc/drugs/belantamab-mafodotin/>, <https://onco.cc/drugs/pomalidomide/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/bortezomib/> ;
  onco:companies <https://onco.cc/companies/gsk/> .